Study wrapper · #1027
Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.
Editor's note
A rigorous multi-method pharmacovigilance analysis of FAERS data, with semaglutide featuring prominently among the class-level and drug-specific safety signals. Disproportionality analyses of spontaneous reports can flag potential associations but cannot establish incidence, relative risk, or causation, as the authors explicitly note. The reproducibility across a second database (JADER) strengthens the signal detection, but findings should be read as pointers for further study rather than confirmed risks.
Plain-language abstract
This large analysis of an FDA adverse-event reporting database identified safety signals for GLP-1 receptor agonists, mainly gastrointestinal and hepatobiliary events, with semaglutide showing signals for cyclic vomiting, optic ischemic neuropathy, and suicidal ideation. The authors stress these are hypothesis-generating signals, not measures of actual risk.